Synergistic antitumor activity of lenalidomide with the BET bromodomain inhibitor CPI203 in bortezom...
Synergistic antitumor activity of lenalidomide with the BET bromodomain inhibitor CPI203 in bortezomib-resistant mantle cell lymphoma
About this item
Full title
Author / Creator
Moros, A , Rodríguez, V , Saborit-Villarroya, I , Montraveta, A , Balsas, P , Sandy, P , Martínez, A , Wiestner, A , Normant, E , Campo, E , Pérez-Galán, P , Colomer, D and Roué, G
Publisher
London: Nature Publishing Group UK
Journal title
Language
English
Formats
Publication information
Publisher
London: Nature Publishing Group UK
Subjects
More information
Scope and Contents
Contents
Bortezomib therapy has shown promising clinical activity in mantle cell lymphoma (MCL), but the development of resistance to proteasome inhibition may limit its efficacy. To unravel the factors involved in the acquisition of bortezomib resistance
in vivo
, immunodeficient mice were engrafted with a set of MCL cell lines with different levels...
Alternative Titles
Full title
Synergistic antitumor activity of lenalidomide with the BET bromodomain inhibitor CPI203 in bortezomib-resistant mantle cell lymphoma
Authors, Artists and Contributors
Identifiers
Primary Identifiers
Record Identifier
TN_cdi_proquest_miscellaneous_1622610636
Permalink
https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_proquest_miscellaneous_1622610636
Other Identifiers
ISSN
0887-6924
E-ISSN
1476-5551
DOI
10.1038/leu.2014.106
